Your session is about to expire
← Back to Search
Rituximab or Tocilizumab for Immune-Related Side Effects
Study Summary
This trial will test how well two drugs work to treat side effects in people getting immunotherapy for cancer.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2016 Phase 2 & 3 trial • 86 Patients • NCT03002038Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- You have a history of a condition called diverticulitis or other lower gastrointestinal (GI) conditions that could increase the risk of developing holes in the intestines.You have a preexisting condition that affects your brain or causes seizures.You have had a severe allergic reaction in the past to rituximab or tocilizumab, or to similar medications.You have advanced solid tumors and have experienced certain immune-related side effects from immune checkpoint inhibitors. To determine the appropriate treatment, your medical oncologist and a specialist (such as a rheumatologist or dermatologist) will evaluate your condition. They may recommend therapy with rituximab or tocilizumab, depending on the specific side effect you have. For example, if you have a skin condition, rituximab may be used, while tocilizumab may be used for lung or heart-related issues.You have severe heart disease that is classified as New York Heart Association III or IV.
- Group 1: Tocilizumab
- Group 2: Rituximab
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Are participants being accepted for this research initiative?
"As per the information posted on clinicaltrials.gov, this medical study is actively recruiting patients and was last updated on April 7th 2022. The trial first began accepting applications from participants on September 25th 2020."
Has the Food and Drug Administration granted approval for Rituximab?
"Our team has conservatively graded Rituximab's safety as a 2 since it is currently being studied in Phase 2 trials, with data pointing to its security but not yet proving its effectiveness."
What is the aggregate amount of people participating in this medical trial?
"Affirmative. Clinicaltrials.gov provides evidence that this trial, inaugurated on September 25th 2020, is actively seeking participants. 30 individuals are being sought from 3 different medical centres."
Have scientists previously conducted research using Rituximab?
"Rituximab's research first began at National Institutes of Health Clinical Center in 1993, and 1020 have been concluded since then. Of the current 470 clinical trials taking place worldwide, a notable amount are conducted out of Baltimore, Maryland."
For what purposes is Rituximab frequently utilized?
"Rituximab is traditionally prescribed to combat diffuse large b-cell lymphoma (dlbcl). It has also been found effective for the treatment of systemic juvenile idiopathic arthritis (sjia), and other varieties of B-Cell Lymphomas, such as Polyangiitis."
Share this study with friends
Copy Link
Messenger